Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
The substrate potentials of antituberculosis drugs on solute carrier (SLC) transporters are not well characterized to date, despite a well-established understanding of their drug dispositions and pharmacokinetics. In this study, we investigated comprehensively the substrate potentials of the 22 currently available antituberculosis drugs for SLC family transporter-mediated uptake, using Xenopus laevis oocytes and stably transfected HEK-293 cells in vitro The result suggested that ethambutol, isoniazid, amoxicillin, and prothionamide act as novel substrates for the SLC transporters. In addition, in the presence of representative transporter inhibitors, the uptake of the antituberculosis drugs was markedly decreased compared with the uptake in the absence of inhibitor, suggesting involvement of the corresponding transporters. A cellular uptake study was performed, and the Km values of ethambutol were found to be 526.1 ± 15.6, 212.0 ± 20.1, 336.8 ± 20.1, and 455.0 ± 28 μM for organic cation transporter 1 (OCT1), OCT2, OCTN1, and OCTN2, respectively. Similarly, the Km of prothionamide was 805.8 ± 23.4 μM for OCT1, while the Km values of isoniazid and amoxicillin for organic anion transporter 3 (OAT3) were 233.7 ± 14.1 and 161.4 ± 10.6 μM, respectively. The estimated in vivo drug-drug interaction indexes from in vitro transporter inhibition kinetics for verapamil, probenecid, and ibuprofen against ethambutol, prothionamide, isoniazid, and amoxicillin were found to show potential for clinical drug interactions. In conclusion, this is the first study that demonstrated 22 antituberculosis drug interactions with transporters. This study will be helpful for mechanistic understanding of the disposition, drug-drug interactions, and pharmacokinetics of these antituberculosis drugs.
Arakawa,
Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5.
2012, Pubmed,
Xenbase
Arakawa,
Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5.
2012,
Pubmed
,
Xenbase Bi,
In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation.
2012,
Pubmed Chen,
Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.
2010,
Pubmed Collier,
Two cases of ethambutol nephrotoxicity.
1976,
Pubmed Fredriksson,
The solute carrier (SLC) complement of the human genome: phylogenetic classification reveals four major families.
2008,
Pubmed Gebhart,
Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.
2007,
Pubmed Giacomini,
Membrane transporters in drug development.
2010,
Pubmed Hagenbuch,
Drug uptake systems in liver and kidney: a historic perspective.
2010,
Pubmed Harries,
Epidemiology and interaction of diabetes mellitus and tuberculosis and challenges for care: a review.
2013,
Pubmed Hartkoorn,
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
2007,
Pubmed Hirano,
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans.
2004,
Pubmed Ho,
Transporters and drug therapy: implications for drug disposition and disease.
2005,
Pubmed Ito,
Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.
1998,
Pubmed Kajosaari,
Cyclosporine markedly raises the plasma concentrations of repaglinide.
2005,
Pubmed Kerb,
Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
2006,
Pubmed Kim,
Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry.
2015,
Pubmed Kusuhara,
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.
1999,
Pubmed
,
Xenbase Lau,
effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
2007,
Pubmed Leonhardt,
Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters.
2010,
Pubmed Li,
Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters.
2006,
Pubmed Maeda,
Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells.
2008,
Pubmed Maeda,
Identification of influx transporter for the quinolone antibacterial agent levofloxacin.
2007,
Pubmed
,
Xenbase Merino,
Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion.
2006,
Pubmed Mukherjee,
Programmes and principles in treatment of multidrug-resistant tuberculosis.
2004,
Pubmed Pan,
Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy.
2013,
Pubmed Parvez,
Erratum for Parvez et al., "Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters In Vitro".
2018,
Pubmed Parvez,
Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake.
2016,
Pubmed
,
Xenbase Parvez,
Evaluation of para-Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro.
2017,
Pubmed Parvez,
Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family.
2016,
Pubmed Peloquin,
Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids.
1999,
Pubmed Sandström,
Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats.
1999,
Pubmed Shanson,
The effect of probenecid on serum amoxycillin concentrations up to 18 hours after a single 3 g oral dose of amoxycillin: possible implications for preventing endocarditis.
1984,
Pubmed Shin,
Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis.
2003,
Pubmed Song,
Genetic variants of the organic cation transporter 2 influence the disposition of metformin.
2008,
Pubmed Te Brake,
Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol.
2016,
Pubmed Temmerman,
Acute isoniazid intoxication: seizures, acidosis and coma.
1999,
Pubmed Thwaites,
D-cycloserine transport in human intestinal epithelial (Caco-2) cells: mediation by a H(+)-coupled amino acid transporter.
1995,
Pubmed Tirona,
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.
2003,
Pubmed Vanwert,
Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin.
2008,
Pubmed
,
Xenbase Vavricka,
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
2002,
Pubmed
,
Xenbase Wang,
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine.
2008,
Pubmed Winter,
Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects.
2015,
Pubmed Xu,
Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.
2017,
Pubmed Zhang,
Transporter-mediated drug-drug interactions.
2011,
Pubmed
